Clinical Trials on Infant, Low Birth Weight in Hong Kong

Total 83 results

The University of Hong Kong

Completed

A Study Investigating Whether Low Dose Eyedrops for Pupil Dilation is as Effective and Safe as Standard Dose Eyedrops in Examination for Retinopathy of Prematurity.

Retinopathy of Prematurity

Hong Kong
Chinese University of Hong Kong

Recruiting

A Genome-Wide Association Study for Neonatal Diseases

Necrotizing Enterocolitis | Neonatal Disease

Hong Kong
The University of Hong Kong

Enrolling by invitation

Combined Activity and Cognitive Intervention for ICU Survivors

Delirium | Cognitive Function | Post Intensive Care Syndrome | ARDS: Acute Respiratory Distress Syndrome | Loss of Muscle Mass | Loss of Muscle Strength

Hong Kong
Mononuclear Therapeutics Ltd.
Chinese University of Hong Kong; China Spinal Cord Injury Network

Unknown

Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia

Anemia, Neonatal | Hypoxic-Ischemic Encephalopathy | Hypoxia Neonatal | Cerebral Ischemia of Newborn

Hong Kong
Ajou University School of Medicine
Seoul National University Hospital; Korea University; Gangnam Severance Hospital and other collaborators

Completed

The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia (BPD)

Premature Birth | Bronchopulmonary Dysplasia | Infant, Very Low Birth Weight

Korea, Republic of
KK Women's and Children's Hospital
National University Hospital, Singapore; University of Malaya; Aga Khan University and other collaborators

Active, not recruiting

Pediatric Acute Respiratory Distress Syndrome Asia Study (PARDS Asia)

Acute Respiratory Distress Syndrome | Mechanical Ventilation | Pediatric Intensive Care Unit

Singapore, China, Thailand, Malaysia, Pakistan, Indonesia, India, Hong Kong, Japan, Vietnam
Gelb, Arthur F., M.D.
The Hospital for Sick Children; Stony Brook University; Miller Children's & Women...

Recruiting

Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis

Cystic Fibrosis in Children

United States
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy (FIREFLEYE)

Retinopathy of Prematurity (ROP)

Spain, Singapore, Hong Kong, Korea, Republic of, Malaysia, Japan, Taiwan, Sweden, Portugal, Belgium, Argentina, Bulgaria, Italy, Austria, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Poland, Romania, Russian Federation, Slov... and more
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Malabsorption Syndromes | Cystic Fibrosis | Steatorrhea | Exocrine Pancreatic Insufficiency

United States, Canada
University of South Florida
National Cancer Institute (NCI)

Terminated

Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer

Cancer

United States
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis

United States, Hungary, Israel, South Africa, Spain
Eloxx Pharmaceuticals, Inc.

Completed

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

Cystic Fibrosis

United States, Canada
University of North Carolina, Chapel Hill
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Safety of Sildenafil in Premature Infants (SIL02)

Bronchopulmonary Dysplasia

United States, Canada
Novartis Pharmaceuticals

Completed

Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

Cystic Fibrosis

United States
Solvay Pharmaceuticals

Completed

Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

Cystic Fibrosis | Pancreatic Exocrine Insufficiency

United States
First Wave Bio, Inc.

Completed

OPTION 2: A Trial to Assess the Safety and Efficacy of MS1819 in Enteric Capsules in Patients With Cystic Fibrosis

Cystic Fibrosis (CF) | Exocrine Pancreatic Insufficiency (EPI)

United States, Poland
First Wave Bio, Inc.

Completed

OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis (OPTION)

Cystic Fibrosis (CF) | Exocrine Pancreatic Insufficiency (EPI)

United States, Poland
PTC Therapeutics

Terminated

Study of Ataluren (PTC124) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Spain, Belgium, Israel, Italy, Sweden
University of Massachusetts, Worcester
Cystic Fibrosis Foundation

Completed

Use of Formula Fortified With DHA in Infants With Cystic Fibrosis (DHA)

Cystic Fibrosis

United States
Genentech, Inc.

Completed

A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, Canada
Aridis Pharmaceuticals, Inc.

Recruiting

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Cystic Fibrosis

United States
Calithera Biosciences, Inc

Completed

Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Canada
PTC Therapeutics
Cystic Fibrosis Foundation

Completed

Extension Study of Ataluren (PTC124) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, Spain, Canada, Germany, Israel, Italy, Netherlands, Sweden, United Kingdom
Vertex Pharmaceuticals Incorporated
Moderna, Inc

Recruiting

A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, United Kingdom, Australia, Canada
Corbus Pharmaceuticals Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

Cystic Fibrosis

Belgium, United States, United Kingdom, Italy, France, Germany, Poland
PTC Therapeutics
Cystic Fibrosis Foundation; ECFS-Clinical Trial Network (ECFS-CTN)

Completed

Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)

Cystic Fibrosis

United States, Spain, United Kingdom, Netherlands, Germany, France, Belgium, Italy, Australia, Argentina, Brazil, Bulgaria, Canada, Greece, Israel, Poland
Seattle Children's Hospital
National Heart, Lung, and Blood Institute (NHLBI); Cystic Fibrosis Foundation; CF Therapeutics Development Network Coordinating Center

Completed

Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Cystic Fibrosis

United States, United Kingdom, Germany, Spain, Switzerland, Canada, Netherlands, Italy, Ireland, Sweden, France, Denmark
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Terminated

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation (DISCOVER)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

Cystic Fibrosis

United States, Belgium, Netherlands, United Kingdom
Horizon Pharma USA, Inc.
Forest Laboratories

Completed

MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

Cystic Fibrosis

United States, Australia, Israel, New Zealand, Canada
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis

Cystic Fibrosis

United States
Anthera Pharmaceuticals

Completed

Open-Label Phase III Long-Term Safety Trial of Liprotamase (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Vertex Pharmaceuticals Incorporated

Completed

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

Cystic Fibrosis

United States, Belgium, Netherlands, Australia, Germany, Ireland, United Kingdom
AbbVie
Janssen Research & Development, LLC; Forest Laboratories

Completed

Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy

Cystic Fibrosis

United States
PTC Therapeutics
Cystic Fibrosis Foundation

Completed

Study of Ataluren (PTC124™) in Cystic Fibrosis

Cystic Fibrosis

United States, France, Belgium, United Kingdom, Spain, Canada, Germany, Israel, Italy, Netherlands, Sweden
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation

Cystic Fibrosis

United States, Canada, Germany, United Kingdom
Genentech, Inc.

Terminated

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

Cystic Fibrosis

United States
Laurent Pharmaceuticals Inc.
Cystic Fibrosis Foundation

Completed

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults (APPLAUD)

Cystic Fibrosis

United States, Australia, Canada
Anthera Pharmaceuticals

Unknown

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Lithuania, Poland, Spain, United Kingdom
AbbVie
VIVUS LLC; Cystic Fibrosis Foundation; Digestive Care, Inc.; Nestle Health Science

Terminated

Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)

Fibrosing Colonopathy

United States
CF Therapeutics Development Network Coordinating...
Cystic Fibrosis Foundation

Completed

The EPIC Observational Study (EPIC OBS)

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)

Cystic Fibrosis

United States, France, Germany
Anthera Pharmaceuticals

Completed

SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States, Hungary, Israel, Poland, Spain, Canada, Czechia
PTC Therapeutics

Terminated

Extension Study of Ataluren in Participants With Nonsense Mutation Cystic Fibrosis

Cystic Fibrosis

United States, Spain, France, Belgium, United Kingdom, Australia, Brazil, Bulgaria, Canada, Germany, Israel, Italy, Netherlands, Poland, Argentina, Greece
Novartis

Terminated

Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Subjects (EVOLVE)

Cystic Fibrosis

United States, Argentina, Brazil, Bulgaria, Canada, Chile, Lithuania, Mexico
Vertex Pharmaceuticals Incorporated

Completed

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation (TRAFFIC)

Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

United States, Germany, Canada, Netherlands, Czech Republic, Italy, Ireland, Sweden, United Kingdom, Australia, France
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Cystic Fibrosis

United States, France, United Kingdom, Germany, Australia, New Zealand, Belgium
Vertex Pharmaceuticals Incorporated

Completed

Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor

Cystic Fibrosis

United States, France, United Kingdom, Germany, Belgium, Denmark, Canada, Australia, Sweden

Clinical Trials on Infant, Low Birth Weight in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations